Announced
Synopsis
Backed by PE Fund, Stada Pharmaceuticals, worlwide developer of pharmaceuticals products, bidds for UPSA Sas, Bristol-Myers Squibb French business, which is engaged in painkillers manufacturing, alongside with a number of PE funds such as: BC Partners, private equity firm specializing in investments in acquisitions and growth capital, CVC Capital Partners, private equity firm specializing in middle market and mature, PAI Partners, private equity firm specializing in leveraged buyouts. The potential deal value is $1,15 billion.
Show Details & Financials
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.